We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+8.99%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
+$21.9B
(+100,205%)
Cap. Flow
-$417M
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$89.3M |
| 2 |
Keysight
KEYS
|
+$86M |
| 3 |
Nike
NKE
|
+$78.3M |
| 4 |
Amphenol
APH
|
+$76.5M |
| 5 |
Comcast
CMCSA
|
+$72.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celanese
CE
|
+$108M |
| 2 |
Monster Beverage
MNST
|
+$97.8M |
| 3 |
Starbucks
SBUX
|
+$79.7M |
| 4 |
Texas Instruments
TXN
|
+$67.3M |
| 5 |
Centene
CNC
|
+$64.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.83% |
| 2 | Financials | 13.42% |
| 3 | Healthcare | 13.25% |
| 4 | Industrials | 9.77% |
| 5 | Consumer Discretionary | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
McCormick & Company Non-Voting
MKC
$13.6B
| $2.28M | 0.01% |
26,906
-66,522
| -71% | -$5.5M |
|
527
Methode Electronics
MEI
$542M
| $2.27M | 0.01% |
57,640
+120
| +0.2% | +$4.36K |
|
528
PACCAR
PCAR
$70.2B
| $2.24M | 0.01% |
42,429
-13,406
| -24% | -$689K |
|
529
RELX
RELX
$62.3B
| $2.23M | 0.01% |
88,499
-326
| -0.4% | -$7.79K |
|
530
Conagra Brands
CAG
$7.29B
| $2.22M | 0.01% |
64,835
+45,344
| +233% | +$1.31M |
|
531
Manhattan Associates
MANH
$9.42B
| $2.21M | 0.01% |
27,762
+20,499
| +282% | +$1.63M |
|
532
iShares MSCI China ETF
MCHI
$6.14B
| $2.21M | 0.01% |
34,510
| – | – |
|
533
Brixmor Property Group
BRX
$9.93B
| $2.21M | 0.01% |
+102,232
| New | +$2.18M |
|
534
NNN REIT
NNN
$9.36B
| $2.2M | 0.01% |
41,073
-184,858
| -82% | -$10.3M |
|
535
Host Hotels & Resorts
HST
$17.1B
| $2.19M | 0.01% |
118,019
-198,673
| -63% | -$3.44M |
|
536
First American
FAF
$7.79B
| $2.17M | 0.01% |
37,260
+4,496
| +14% | +$275K |
|
537
DXC Technology
DXC
$1.68B
| $2.17M | 0.01% |
57,727
-133,256
| -70% | -$4.35M |
|
538
Essential Utilities
WTRG
$11.2B
| $2.15M | 0.01% |
45,866
+1,776
| +4% | +$80K |
|
539
West Pharmaceutical
WST
$23.3B
| $2.15M | 0.01% |
14,300
+3,623
| +34% | +$528K |
|
540
Viavi Solutions
VIAV
$9.41B
| $2.15M | 0.01% |
143,314
+141,630
| +8,410% | +$2.12M |
|
541
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETF
EFAX
$495M
| $2.15M | 0.01% |
+59,238
| New | +$2.08M |
|
542
iShares S&P Mid-Cap 400 Value ETF
IJJ
$8.87B
| $2.1M | 0.01% |
24,614
-410
| -2% | -$33.7K |
|
|
FISV
543
Fiserv Inc
FISV
$27.9B
| $2.09M | 0.01% |
18,116
+1,137
| +7% | +$126K |
|
544
Vanguard Consumer Discretionary ETF
VCR
$5.92B
| $2.09M | 0.01% |
11,049
+896
| +9% | +$164K |
|
545
Neurocrine Biosciences
NBIX
$17.7B
| $2.07M | 0.01% |
19,262
+1,066
| +6% | +$112K |
|
|
BRMK
546
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
| $2.06M | 0.01% |
+161,380
| New | +$1.79M |
|
547
Prudential Financial
PRU
$42.3B
| $2.05M | 0.01% |
21,843
-142
| -0.6% | -$13K |
|
548
Carlyle Secured Lending
CGBD
$710M
| $2.02M | 0.01% |
150,797
-53,423
| -26% | -$740K |
|
549
MSCI
MSCI
$41.5B
| $2M | 0.01% |
7,756
+199
| +3% | +$48.5K |
|
550
Equitable Holdings
EQH
$13.3B
| $1.98M | 0.01% |
+79,778
| New | +$1.85M |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q4 2019 Portfolio in Review
As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
- Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
- Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
- Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
- Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
- Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
- Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
- Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.
Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.